What is BioSerenity?
Headquartered in Paris and Atlanta, BioSerenity operates at the intersection of neurology, sleep medicine, and cardiology. By leveraging the Internet of Medical Things (IoMT) and artificial intelligence, the company provides comprehensive diagnostic tools that generate real-world evidence for healthcare providers and research institutions. Their platform is increasingly recognized as a preferred partner for Contract Research Organizations (CROs) and university medical centers, facilitating a shift toward data-driven, patient-centric clinical outcomes. The company's unique model integrates hardware and software to streamline diagnostic workflows, effectively bridging the gap between complex medical data and actionable clinical insights.
How much funding has BioSerenity raised?
BioSerenity has raised a total of $92.9M across 3 funding rounds:
Angel/Seed
$3.4M
Series A
$17.9M
Series B
$71.7M
Angel/Seed (2015): $3.4M with participation from Kurma Partners and IdInvest Partners
Series A (2017): $17.9M led by Idinvest Partners and LBO France
Series B (2019): $71.7M, investors not publicly disclosed
Key Investors in BioSerenity
Kurma Partners
Kurma Partners is a prominent player in funding healthcare and biotechnology ventures across Europe, specializing in transforming disruptive scientific discoveries into advanced medical solutions.
Idinvest Partners
Idinvest Partners is a mid-market private equity firm founded in 1997 that provides essential financing and strategic support to entrepreneurs throughout various stages of business development.
LBO France
LBO France is a leading investment fund with over 30 years of expertise, focusing on mid-cap and small-cap investments in innovative sectors such as digital health and sustainable value creation.
What's next for BioSerenity?
With the support of major enterprise-level funding, BioSerenity is poised to deepen its investment in AI-driven diagnostic capabilities and expand its footprint within the global digital health ecosystem. The company is expected to prioritize the scaling of its IoMT infrastructure, enabling more seamless integration with existing hospital systems and research networks. As the demand for remote monitoring and real-world evidence continues to rise, BioSerenity's strategic focus will likely center on enhancing its diagnostic accuracy and broadening its therapeutic reach. By maintaining its commitment to high-quality clinical data, the firm is well-positioned to remain a leader in the next generation of medical technology innovation.
See full BioSerenity company page
